Pupillary unrest, opioid intensity, and the impact of environmental stimulation on respiratory depression

Rachel Eshima McKay, Michael A Kohn, Merlin D Larson, Rachel Eshima McKay, Michael A Kohn, Merlin D Larson

Abstract

Opioid-induced respiratory depression (OIRD) confers significant morbidity, but its onset can be challenging to recognize. Pain or stimulation effects of conversation may mask or attenuate common clinical manifestations of OIRD. We asked whether pupillary unrest could provide an objective signal of opioid exposure, and whether this signal would be independent from the confounding influence of extrinsic stimulation. We conducted a cross-over trial of healthy volunteers using identical remifentanil infusions separated by a washout period; in both, pupillary unrest in ambient light (PUAL) was measured at 2.5-min intervals. During one infusion, investigators continuously engaged the subject in conversation, while in the other, a quiet environment was maintained; measures of respiratory depression were compared under each condition. We tested PUAL's relationship to estimated opioid concentration under quiet conditions, measured PUAL's discrimination of lower versus higher opioid exposure using receiver operating characteristic (ROC) analysis, and assessed the effect of stimulation on PUAL versus opioid using mixed effects regression. Respiratory depression occurred more frequently under quiet conditions (p < 0.0001). Under both conditions, PUAL declined significantly over the course of the remifentanil infusion and rose during recovery (p < 0.0001). PUAL showed excellent discrimination in distinguishing higher versus absent-moderate opioid exposure (AUROC = 0.957 [0.929 to 0.985]), but was unaffected by interactive versus quiet conditions (mean difference, interactive - quiet = - 0.007, 95% CI - 0.016 to 0.002). PUAL is a consistent indicator of opioid effect, and distinguishes higher opioid concentrations independently of the stimulating effects of conversational interaction. Under equivalent opioid exposure, conversational interaction delayed the onset and minimized the severity of OIRD.Clinical trial registration: NCT04301895.

Keywords: Infrared pupillometry; Monitoring drug effects; Opioid induced respiratory depression; Opioid intoxication; Opioid medication; Opioid related patient safety; pupillary responses.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Mean transcutaneous CO2 measurements during the 10-min remifentanil infusion and 25-min recovery period. Respiratory depression was more pronounced during the quiet versus interactive conditions, with CO2 increasing 37% versus 21% above baseline values respectively (p = 0.0002)
Fig. 2
Fig. 2
a Oxyhemoglobin desaturation occurred more frequently (in 19/20 in versus 10/20 subjects) and earlier (median onset 6.2 versus 9.6 min) under quiet compared to interactive conditions (HR 0.135, p < 0.001, conditional Cox regression). In contrast to respiratory outcomes, PUAL decline did not differ under quiet versus interactive conditions. b Paired data shows onset of oxyhemoglobin desaturation in subjects under quiet and interactive conditions
Fig. 3
Fig. 3
PUAL declined progressively as opioid concentration increased during the 10-min remifentanil infusion, from an average of 0.264 at baseline to 0.022 by 10 min under quiet conditions, and recovered as the infusion was discontinued (p 

Fig. 4

In 20 subjects under quiet…

Fig. 4

In 20 subjects under quiet conditions, PUAL showed excellent discrimination between high versus…

Fig. 4
In 20 subjects under quiet conditions, PUAL showed excellent discrimination between high versus absent-moderate opioid effect: AUROC = 0.9459 (0.8957—0.9961) under quiet conditions and 0.9671 (0.9384–0.9958) under interactive conditions (p = 0.3588 for difference in ROC area under the two conditions). Compared to PUAL, CO2 showed weaker discrimination between high versus absent-moderate opioid effect: AUROC = 0.8079 (0.7284–0.8874) under quiet conditions and 0.6501 (0.5480–0.7521) under interactive conditions (p = 0.0202 for difference in CO2 ROC area under the two contrasting conditions, p = 0.0034 for difference between CO2 versus PUAL ROC area under quiet conditions, and p < 0.0001 for difference between CO2 versus PUAL ROC area under interactive conditions)

Fig. 5

Overall, ≥ 90% PUAL suppression…

Fig. 5

Overall, ≥ 90% PUAL suppression occurred in 19/20 of subjects during quiet conditions…

Fig. 5
Overall, ≥ 90% PUAL suppression occurred in 19/20 of subjects during quiet conditions versus 18/20 subjects during interactive conditions. The proportion of subjects reaching ≥ 90% PUAL suppression under each condition did not differ significantly, HR 1.193 (95% CI 0.624–2.278), p = 0.593
Fig. 4
Fig. 4
In 20 subjects under quiet conditions, PUAL showed excellent discrimination between high versus absent-moderate opioid effect: AUROC = 0.9459 (0.8957—0.9961) under quiet conditions and 0.9671 (0.9384–0.9958) under interactive conditions (p = 0.3588 for difference in ROC area under the two conditions). Compared to PUAL, CO2 showed weaker discrimination between high versus absent-moderate opioid effect: AUROC = 0.8079 (0.7284–0.8874) under quiet conditions and 0.6501 (0.5480–0.7521) under interactive conditions (p = 0.0202 for difference in CO2 ROC area under the two contrasting conditions, p = 0.0034 for difference between CO2 versus PUAL ROC area under quiet conditions, and p < 0.0001 for difference between CO2 versus PUAL ROC area under interactive conditions)
Fig. 5
Fig. 5
Overall, ≥ 90% PUAL suppression occurred in 19/20 of subjects during quiet conditions versus 18/20 subjects during interactive conditions. The proportion of subjects reaching ≥ 90% PUAL suppression under each condition did not differ significantly, HR 1.193 (95% CI 0.624–2.278), p = 0.593

References

    1. Centers for Disease Control and Prevention. Drug overdose death rates, by drug type, sex, age, race, and Hispanic origin: United States, selected years 1999–2017. 2018. . Accessed 18 Dec 2019
    1. Danovitch I, Vanle B, Van Groningen N, Ishak W, Nuckols T. Opioid overdose in the hospital setting: a systematic review. J Addict Med. 2020;14:39–47. doi: 10.1097/ADM.0000000000000536.
    1. Overdyk FJ, Dowling O, Marino J, Qiu J, Chien H-L, Erslon M, Morrison N, Harrison B, Dahan A, Gan TJ. Association of opioids and sedatives with increased risk of in-hospital cardiopulmonary arrest from an administrative database. PLoS ONE. 2016;11(2):e0150214. doi: 10.1371/journal.pone.0150214.
    1. Lee LA, Caplan RA, Stephens LS, Posner KL, Terman GW, Voepel-Lewis T, Domino KB. Postoperative opioid-induced respiratory depression: a closed claims analysis. Anesthesiology. 2015;122:659–665. doi: 10.1097/ALN.0000000000000564.
    1. Khanna AK, Hoppe P, Saugel B. Automated continuous noninvasive ward monitoring: future directions and challenges. Crit Care. 2019;23(1):194–199. doi: 10.1186/s13054-019-2485-7.
    1. Kharasch ED, Hoffer C, Walker A, Sheffels P. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther. 2003;73:199–208. doi: 10.1067/mcp.2003.30.
    1. Rollins MD, Feiner JR, Lee JM, Shah S, Larson M. Pupillary effects of high-dose opioid quantified with infrared pupillometry. Anesthesiology. 2015;121:1037–1044. doi: 10.1097/ALN.0000000000000384.
    1. Montana MC, Juriga L, Sharma A, Kharasch ED. Opioid sensitivity in children with and without obstructive sleep apnea. Anesthesiology. 2019;130:936–945. doi: 10.1097/ALN.0000000000002664.
    1. Usui S, Stark L. A model for nonlinear stochastic behavior of the pupil. Biol Cybern. 1982;45:13–21. doi: 10.1007/BF00387209.
    1. Stark L. Pupillary control system: its nonlinear adaptive and stochastic engineering design characteristics. Fed Proc. 1969;28:52–64.
    1. Bokoch MP, Behrends M, Neice A, Larson MD. Fentanyl, an agonist at the µu-opioid receptor, depresses pupillary unrest. Auton Neurosci. 2015;189:68–74. doi: 10.1016/j.autneu.2015.01.004.
    1. Neice AE, Behrends M, Bokoch MP, Seligman KM, Conrad NM, Larson MD. Prediction of opioid analgesic efficacy by measurement of pupillary unrest. Anesth Analg. 2017;124:915–921. doi: 10.1213/ANE.0000000000001728.
    1. Turnbull PRK, Irani N, Lim N, Phillips JR. Origins of pupillary hippus in the autonomic nervous system. Invest Ophthalmol Vis Sci. 2017;58:197–203. doi: 10.1167/iovs.16-20785.
    1. McKay RE, Neice AE, Larson MD. Pupillary unrest in ambient light and prediction of opioid responsiveness: case report on its utility in the management of two patients with challenging acute pain conditions. Anesth Analg Pract. 2018;10:279–282.
    1. Wilhelm B, Giedke H, Ludtke H, Bittner E, Hofmann A, Wilhelm H. Daytime variations in central nervous system activation measured by a pupillographic sleepiness test. J Sleep Res. 2001;10:1–7. doi: 10.1046/j.1365-2869.2001.00239.x.
    1. Behrends M, Larson MD, Neice AE, Bokoch MP. Suppression of pupillary unrest by general anesthesia and propofol sedation. J Clin Monit Comput. 2019;33:317–323. doi: 10.1007/s10877-018-0147-y.
    1. Smith JD, Masek GA, Ichonose LY, Watanabe T, Stark L. Single neuron activity in the pupillary system. Brain Res. 1970;24:219–234. doi: 10.1016/0006-8993(70)90102-2.
    1. Joshi S, Li Y, Kalwani RM, Gold JI. Relationships between pupil diameter and neuronal activity in the locus coeruleus, colliculi, and cingulate cortex. Neuron. 2016;89:221–234. doi: 10.1016/j.neuron.2015.11.028.
    1. Kobelt P, Burke K, Renker P. Evaluation of a standardized sedation assessment for opioid administration in the post anesthesia care unit. Pain Manage Nurs. 2014;15:672–681. doi: 10.1016/j.pmn.2013.11.002.
    1. Lang E, Kaplia A, Shlugman D, Hoke JF, Sebel PS. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology. 1996;85:721–728. doi: 10.1097/00000542-199610000-00006.
    1. Olofsen E, Boom M, Niewenhuijs D, Sarton E, Teppema L, Aarts L, Dahan A. Modeling the non-steady state respiratory effects of remifentanil in awake and propofol-sedated healthy volunteers. Anesthesiology. 2010;112:1382–1395. doi: 10.1097/ALN.0b013e3181d69087.
    1. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology. 1997;86:24–43. doi: 10.1097/00000542-199701000-00005.
    1. Egan TD, Lemmens HJM, Fiset P, Hermann DJ, Muir KT, Stansky DJ, Shafer SL. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology. 1993;79:881–893. doi: 10.1097/00000542-199311000-00004.
    1. Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain. Anaesthesia. 1981;36:37–39. doi: 10.1111/j.1365-2044.1981.tb08596.x.
    1. Borghjerg F, Nielsen K, Franks J. Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers. Pain. 1996;64:123–128. doi: 10.1016/0304-3959(95)00088-7.
    1. Lentschener C, Tostivint P, White P, Gentili ME, Ozier Y. Opioid-induced sedation in the postanesthesia care unit does not insure adequate pain relief: a case-control study. Anesth Analg. 2007;105:1193–1197. doi: 10.1213/01.ane.0000281441.93304.e3.
    1. Janneto PJ, Bratanow NC. Pharmacogenomic considerations in the opioid management of pain. Genom Med. 2010;2(9):66–70. doi: 10.1186/gm187.
    1. Marateb HR, Mansourian M, Adibi P, Farina D. Manipulating measurement scales in medical statistical analysis and data mining: a review of methodologies. J Res Med Sci. 2014;19:47–56.
    1. Murray RB, Adler MW, Korczyn AD. The pupillary effects of opioids. Life Sci. 1983;33:495–509. doi: 10.1016/0024-3205(83)90123-6.
    1. Larson MD. Mechanism of opioid-induced pupillary effects. Clin Neurophysiol. 2008;119:1358–1364. doi: 10.1016/j.clinph.2008.01.106.
    1. Charier D, Vogler M-C, Zantour D, Pichot V, Martins-Baltar A, Courbon M, Roche F, Vassal F, Molliex S. Assessing pain in the postoperative period: Anesthesia Nociception Index versus pupillometry. Br J Anaesth. 2019;123:e322–e327. doi: 10.1016/j.bja.2018.09.031.

Source: PubMed

3
購読する